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Genetic Dissection of Familial Colorectal Cancer
Peltomäki P . 
Department of Medical Genetics, University of Helsinki, Finland
Among families with clinical presentation of hereditary
nonpolyposis colorectal cancer, 30-70% show no germline DNA
mismatch repair (MMR) gene mutations. We previously detected
‘hidden’ MMR gene defects in 42% of such families, leaving the
remaining 58% ‘truly’ mutation negative. Families with no
demonstrable germline mutations in MMR genes differ from
mutation-positive families in several essential respects, including
later age at onset, generally more distal tumour location, and
less frequent occurrence of extracolonic cancers (Renkonen et al.
2003), suggesting a different genetic basis for the latter families. 
To obtain clues to the nature of cancer susceptibility in families
with no MMR gene mutations, tumours from such families were
investigated. These were found to display a unique molecular
and clinicopathological profile characterized by a lack of genomic
instability (MIN or CIN), normal (membranous) β-catenin, and
low frequency of TP53 mutations (Abdel-Rahman et al. 2005).
These features distinguish MMR gene mutation negative families
from both HNPCC families linked to MMR defects and sporadic
cases and should facilitate the identification of novel predisposition
genes and pathways in such families.
As an alternative and complementary approach, genetic lin-
kage analysis may be used to identify new cancer predisposition
genes. Previous linkage and other studies suggest that as yet
unidentified, highly or moderately penetrant colorectal cancer
susceptibility genes are likely to exist. A collaborative effort for
the identification of novel susceptibility genes in Polish families
will be discussed.  
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Mutations Causing FAP in the Polish Population
P³awski A., Podralska M., S³omski R.
Institute of Human Genetics, Polish Academy of Sciences, Poznañ
Familial adenomatous polyposis (FAP) is an autosomal
dominant predisposition to initiate numerous polyps in the colon
and rectum which develop into carcinoma if left untreated. FAP
is caused by inherited or germline mutations in the APC gene.
Early recognition of mutation carriers is very important for the
medical treatment of persons from the high-risk group. It is
estimated that several hundred Polish FAP families will be
subjected to genetic testing. The DNA bank for Polish FAP
patients at the Institute of Human Genetics in Poznañ was
established in 1997. FAP diagnoses were performed in
cooperating health centres. 620 DNA samples from persons
belonging to 240 FAP families were collected. 280 patients
were diagnosed with FAP; 215 persons belong to the risk group
and 67 persons are excluded from the risk group. The entire
APC gene coding sequence was screened for mutations in 220
families. APC gene mutations were identified in 105 Polish FAP
families. Twenty-nine of them have not been described before.
Seven mutation types recurred two or more times. Recurrent
mutations were detected in 52% of diagnosed families. 90
persons without mutations in the APC gene were further
examined for occurrence of MYH gene mutations. Two of the
most frequent mutations of the MYH gene (Y165C and G382D)
found in this gene occurred in a heterozygotic system in 13%
of patients. In the investigations of the MYH gene, no other
mutations in the coding sequence were recorded. The results
indicate that in our group of patients with diagnosed FAP but
without mutation in the APC gene, the proportion of the
mutation in the MYH gene has a minor impact on
preconditioning the disease.
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Germline mutations in the DNA mismatch repair genes
MSH2 and MLH1 account for a significant proportion of
hereditary non-polyposis colorectal cancer (HNPCC) families.
One approach by which development of an efficient DNA
testing procedure can be implemented is to describe the nature
and frequency of common mutations in particular ethnic
groups. Two hundred and twenty-six patients from families
matching the Amsterdam II diagnostic criteria or suspected
HNPCC criteria were screened for MSH2 and MLH1 germline
mutations. Fifty different pathogenic mutations were found,
twenty-five in MSH2 and twenty-five in MLH1. Twenty-seven
of these had not previously been described in other
populations. Among our 77 families with MSH2 or MLH1
mutations, 51 (67.5%) were affected by recurrent mutations
including 38 found at least twice in our own series. Two of the
most frequent alterations were a substitution of A to T at the
splice donor site of intron 5 of MSH2 and a missense change
(A681T) of MLH1 found in 10 and 8 families, respectively.
Among large deletions detected by the MLPA assay, exon 9
deletions in the MSH2 gene were found in two families. Our
results indicate that a screening protocol specific for the Polish
population that is limited to the detection of all reported
mutations will result in the identification of the majority of
changes present in MLH1 and MSH2 genes in Polish HNPCC
kindreds.
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A Ai im m: :   The aim of the study was to describe the frequency and
nature of MSH6 germline mutations in Polish patients with
colorectal, endometrial and ovarian cancers. 
M Ma at te er ri ia al ls s   a an nd d   m me et th ho od ds s: :   489 colorectal cancer (CRC) cases,
153 endometrial cancer (EC) cases and 179 ovarian cancer
(OC) cases were studied, using immunohistochemistry (IHC),
DNA sequencing, MLPA, DHPLC and ASA-PCR methods.
R Re es su ul lt ts s: :   Seven new alterations and one in other population
were found. Five of them were detected in families with
colorectal, endometrial or ovarian cancer aggregation among
relatives, two in patients with multiple primary tumours and one
in a patient with early onset colorectal cancer.  
C Co on nc cl lu us si io on ns s: :   The MSH6 gene should be investigated for
occurrence of germline abnormalities in probants affected
by CRC, EC or OC and tumours of this type diagnosed
among their relatives. Additionally, an MSH6 examination
should be considered for probants with multiple primary
tumours (one of them is CRC, EC or OC) or for probants with
sporadic, early onset CRC. Laboratory analysis should begin
with MSH6 immunohistochemistry. Then, in cases with no
detectable protein expression, DHPLC/sequencing analysis
of coding regions (starting from exons 4 and 5) should be
performed.
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The population frequencies of the CDKN2A common
variants remain undetermined. In Poland there is a common
variant of CDKN2A: an alanine to threonine substitution
(A148T), which has been detected in other populations. We
have recently shown that it is significantly overrepresented
among Polish melanoma patients when compared to the
general population. Herein we ascertained the prevalence of
the A148T variant in 3,583 unselected cancer cases and 3,000
random control subjects from the same Polish population. We
evaluated eleven different malignancies, representing the
majority of all common cancer sites. A positive association with
the A148T variant was observed for lung cancer (OR 2.0,
p=0.0052). A similar trend, although non-significant after
Bonferroni correction, was observed for colorectal cancer (OR
1.5, p=0.5499). These results suggest that the A148T variant
may be associated with multi-organ cancer risk in the Polish
population.
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It is estimated that about 30% of all neoplasms result from
a high, genetically determined predisposition. During recent
years, a number of genes have been discovered with mutations
responsible for an increased risk of neoplasm occurrence. Genes
associated with a predisposition to hereditary neoplasms include:
BRCA1, BRCA2, Rb1, MSH2, MLH1 and MSH6. In carriers of
the above gene mutations, the risk of neoplastic diseases
increases up to as high as 90%. 
There is also a large group of genes, the constitutional
mutations of which also increase the risk of neoplasm
occurrence in certain organs. These are, among others: NBS1,
NOD2, CHEK2, CYP1B1 and CDKN2A. An occurrence of
mutation in any of the above genes elevates the risk of
neoplasm in a number of organs, including the breast, the
prostate, the colon, the lungs, the larynx, the ovary, the thyroid
and the kidney, as well as of malignant melanoma. Having
developed a number of diagnostic tests, it is now possible to
determine the constitutional status of patients from the risk
groups, followed by implementation of appropriate prophylactic
action.
Among the patients examined at our Centre, the incidence
of BRCA1 gene mutation was 1.5% (3/214), that of CHEK2
(I157T) was 6% (1/18), and that of NOD2 was 10% (6/60). 
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The frameshift NOD2 gene 3020insC mutation is associa-
ted especially with Crohn’s disease, but predisposes also to ma-
ny types of common cancers. We studied the frequency of the
mutant allele in 148 breast cancer women from the Bydgoszcz
region of Poland. The NOD2 mutation was present in 8.8% of
patients. The mean age of mutation carriers at breast cancer dia-
gnosis was 43 years. We did not find any mutation in patients
diagnosed with breast cancer after the age of 50. There was no
association of NOD2 mutation with family breast cancer history.
On the contrary, the frequency of mutation (11.4%) was two ti-
mes higher in the women from families with one case of breast
cancer and with aggregation of other common types of cancer,
especially digestive tract cancers. Low risk of breast cancer in the
mutation carriers seems to be confirmed by the finding of the
3020insC mutation in three healthy parents of probands aged
73, 74 and 83 years, from three separate families.  
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We identified 4,315 unselected incident cases of early-onset
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hospitals between 1996 and 2003. We were able to obtain a
blood sample for DNA analysis from 3,473 of these (80.5%).
All cases were tested for the presence of three founder mutations
in BRCA1. The proportion of cases with a BRCA1 mutation was
5.7%. Of the 198 hereditary cases, 36.4% were described as
either medullary or atypical medullary and 44.5% were ductal.
The tumours in women with BRCA1 mutations were slightly larger,
on average, than non-hereditary tumours (2.4 cm versus 2.2
cm; p=0.1) but were less likely to be node-positive at diagnosis
(35.6% versus 39.6%; p=0.04). 57.1% of the hereditary cases
had a family history of breast or ovarian cancer.  
A significant proportion of breast cancer cases in women
diagnosed in Poland under the age of 50 years are due to
BRCA1 mutations. These cases could not be reliably identified
by family history alone. The association between medullary breast
cancer and the presence of a BRCA1 mutation may be greater
than previously thought, and emphasizes the importance of
recording lymphocytic infiltrates. It is reasonable to offer genetic
testing to women with early-onset breast cancer in Poland and
to their family members. 
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Women with a mutation in BRCA1 or BRCA2 face a lifetime
risk of breast cancer of approximately 80%, and following the
first diagnosis the ten-year risk of contralateral breast cancer is
approximately 30%. It has been shown that both tamoxifen and
oophorectomy prevent contralateral breast cancer, but it is not
clear if there is a benefit to giving tamoxifen to women who have
previously undergone an oophorectomy. Furthermore, the relative
degree of protection in BRCA1 and BRCA2 carriers has not been
well evaluated. We studied 285 women with bilateral breast
cancer and a BRCA1 or BRCA2 mutation, and 751 control
women with unilateral breast cancer and a BRCA1 or BRCA2
mutation in a matched case-control study. Control women were
of similar age and had a similar age of diagnosis of breast
cancer and were followed for as long as the case for a second
primary breast cancer. The history of tamoxifen use for the first
breast cancer was compared between bilateral and unilateral
cases. The multivariate odds ratio for contralateral breast cancer
associated with tamoxifen use was 0.50 for carriers of BRCA1
mutations (95% CI: 0.30 to 0.85) and was 0.42 for carriers of
BRCA2 mutations (95% CI: 0.17 to 1.02). The protective effect
of tamoxifen was not seen among women who had undergone
an oophorectomy (OR=0.83; 95% CI 0.24 to 2.89) but this
subgroup was small. In contrast, a strong protective effect of
tamoxifen was apparent among women who had undergone a
natural menopause (OR=0.44; 95% CI 0.27 to 0.65).
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The aim of this work was to estimate the influence of
paclitaxel on activation and inactivation of different genes
concerned with development of breast cancer by using the matrix
technique. Expression of the genes was calculated in cultures of
breast cancer cells which were put under the influence of
paclitaxel in 60 ng/ml (PI) and 300 ng/ml (PII) doses in
comparison to control cells (K). This made it possible to assess
the influence of this drug on the metabolic cycle of the cells. It
was thus possible to estimate the activity of different families of
genes which participate in carcinogenesis. 
A significant increase of caspase gene expression was
observed in group PI in comparison to the control group
(p<0.001). In group PII no significant differences were observed
in comparison to group K (p>0.05). A significant increase of
activity of antiapoptotic genes was observed in group PI in
comparison to group K (p<0.0001). In the second group a
significant statistically weak decrease in expression was observed
in comparison to the control group (p<0.05). All comparisons
between the second and first group concerning caspases and
apoptotic genes were significantly higher (p<0.0001). 
One of the most important processes in stopping
development of breast cancer is apoptosis. One of them is
anti-apoptosis genes. In this group there are BCl-2 family as
BCL-2, BCL-XL, BCLW, MCL, BFL-1, BCL-G). In the second we
can distinguish genes which accelerate cell death (BAX, BCLX,
BAK, BOK, BAD, BIK, BID, BIM, KRK, MTD, NIP3, BCL-B).
Proapoptotic genes  such as BCL-X are bound with APAF-1 factor.
This process inactivates the release of caspases. In this mechanism
the main role take play changes in keeping of proteins by
mitochondria. In the case of increasing apoptotic factors the
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permeability of the mitochondrial membrane is elevated. This
causes release of APAF-1 and activation of 9 and 3 caspases and
leads to digestion proteins which are important in living of the
cell/cell metabolism. 8 and 10 caspases can be activated by
joining TNF to surface membrane receptors. They can also be
activated by an external signal carried by such receptors as APO1,
IGF1R and TNFR1(2). Signals from these receptors can activate
caspases. TP-53 protein, which causes an increase of products
taking part in the apoptosis process, participates in this process.
It  also leads to the release of cyclin c. 
In the assessment the activities of two groups of genes
concerned with inhibition of apoptosis (BCL2A1, BID, CRADD,
DAD1, BECN1, NOL-3, FADD, DNAI A3, CASP1, and caspase
(caspase 1-14) were compared.
A significant decrease of anti-apoptotic genes was observed,
especially in the second group where levels of paclitaxel were
very high. This indicates that paclitaxel inhibits apoptosis
processes. The study indicates that in the second group where
the level of paclitaxel was five times higher this phenomenon is
obvious. Very high levels of palitaxel are harmful for the cells
and cause considerable damage and necrosis.
It seems obvious that such lowering of apoptotic activity in
group PII should cause a significant decrease of caspases. It can
be explained by a mechanism of inactivation of caspase activity
and apoptotic genes by the drug taxane.
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We obtained blood samples and pedigree information from
3,568 unselected cases of early-onset breast cancer, and from
609 unselected patients with ovarian cancer from various
hospitals situated throughout Poland. Genetic testing was
performed for three founder BRCA1 mutations and mutations
were identified in 273 samples (187 with 5382insC, 22 with
4153delA and 64 with C61G). A mutation was present in 4.3%
of patients with breast cancer and 12.3% of patients with ovarian
cancer. We calculated the risk to age 75 in the first-degree
relatives of carriers using Kaplan-Meir methods. The overall risk
of breast cancer to age 75 in the relatives was 33% and the risk
of ovarian cancer was 15%. The risk for breast cancer was 42%
higher among first-degree relatives of carriers of the C61G
missense mutation, compared to other mutations (HR=1.42;
p=0.10) and the risk for ovarian cancer was lower than average
(OR=0.26; p=0.03). Relatives of women diagnosed with breast
cancer had a higher risk of breast cancer than the relatives of
women diagnosed with ovarian cancer (OR=1.7; p=0.03). The
risks for both breast and ovarian cancer were significantly higher
in sisters of probands than in mothers, indicating that penetrance
appears to be increasing with time. 
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The evidence that BRCA1 mutation carriers are at an increased
prostate cancer risk is mixed and both positive and negative studies
have been published. To establish whether inherited variation in
BRCA1 influences prostate cancer risk in Poland we genotyped
807 cases of prostate cancer and 4,570 controls for the three
founder mutations (C61G, 4153delA and 5382insC). A BRCA1
mutation was seen in 0.9% of cases and 0.5% of controls
(OR=1.8; p=0.26). However, 4153delA was many times more
common in prostate cancer cases (0.5%) than in controls (0.04%)
(OR=11.4; 95% CI 2.1–62; p=0.003). The BRCA1 C61G
mutation was found in 0.4% of cases compared to 0.06% in
controls (OR=5.7; 95% CI 1.1–28; p=0.07). The 5382insC
mutation was not detected in any case, whereas it was seen in
0.4% of controls (p=0.16). None of the seven prostate cancer
cases with a mutation carried the 5382insC mutation, compared
to 17 of 22 individuals with mutations in the control population
(p=0.0005). Our study provides evidence that prostate cancer
risks may be different for particular alleles of BRCA1. 
[13]
Founder Mutations in the BRCA1 Gene in Women with Ovarian 
or Endometrial Cancer 
Magnowski P .
1, Stawicka M.
2,  Górski B.
3, Lubiñski J.
3,
Spaczyñski M.
1
1Klinika Onkologii Ginekologicznej, Katedra Ginekologii i Po³o¿nictwa, Akademia Medyczna,
Poznañ, Poland; 2Onkologiczna Poradnia Genetyczna, OPEN, Poznañ, Poland; 3Oœrodek
Nowotworów Dziedzicznych, Zak³ad Genetyki i Patomorfologii, Pomorska Akademia
Medyczna, Szczecin, Poland
The aim of our study was to estimate the frequency of BRCA1
gene founder mutations in the Polish population. The study group
T Ta ab bl le e   1 1. .   
G Ge en ne es s C Co on nt tr ro ol l    G Gr ro ou up p   P PI I    G Gr ro ou up p   P PI II I   
e ex xp pr re es ss si io on n g gr ro ou up p
apoptotic genes 14.9±12.9 34.2±2.6** 11.75±4.9*
caspases 11.5± 3.9 31.1±17.1** 9.85±2.03
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consisted of 106 consecutive patients affected by ovarian cancer
and 94 with endometrial cancer. The patients have been treated
since 2003 in the Division of Gynecological Oncology at Karol
Marcinkowski University of Medical Sciences in Poznañ. We have
identified BRCA1 gene mutations in 14 of 106 (13.21%)
consecutive patients suffering from ovarian cancer. In the group
of women with endometrial cancer we found the BRCA1
mutation in one patient. Based on the pedigree-clinical criteria
in the group with ovarian cancer we recognised hereditary
breast-ovarian cancer syndrome in 22 women, hereditary
ovarian cancer syndrome in 10 women and Lynch syndrome in
5 patients. In the group of patients affected by endometrial
cancer we found Lynch syndrome in 4 patients (4.2%).    
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Oestrogen influences the growth, differentiation, and
function of breast and several other target tissues by the
oestrogen receptors (ESR). ESRα and ESRβ are the most
important mediators of the response to stimulation by oestrogens
in target tissues. The mitogenic activity of oestrogens has
profound importance in the aetiology and progression of human
breast and gynaecological cancers.
The aim of this study was to investigate the possible
modulating effect of the polymorphisms in ESRα and ESRβ genes
on the risk of developing malignancy in HBOC patients. The
analysis was performed in subjects with HBOC syndrome,
divided into two groups:
1. BRCA1/2 – where germline mutation in the BRCA1 or BRCA2
gene was found
2. BRCAx – subjects with HBOC syndrome but without mutation
in BRCA1/2
– versus a control group of healthy women.
We tested 301 persons for PvuII polymorphism in the ESRα
gene and AluI polymorphism in the ESRβ gene. The TA repeat
in the ESRα gene was analysed in 283 women and 289 women
were examined for CA repeat located in the ESRβ gene.
There were statistically significant differences in the age of
diagnosis between BRCA1/2 and BRCAx groups. The patients
with germline mutations in BRCA genes were younger. The
diagnoses also significantly differed between the two groups
analysed. Carriers of germline mutations in BRCA genes less
frequently developed breast cancer and were more frequently
diagnosed with ovarian cancer.
The SNPs polymorphisms (Pvu II, AluI) in both genes did not
modify the risk of developing cancers in the groups under study.
The length of TA repeats in the ESRα gene showed a strong
association with the risk of malignancy in HBOC families. Carriers
of long/long genotypes were the most frequent in the population
under study so the long/long genotype was chosen as the
reference one. Genotype long/short conferred an increased risk
of malignancy, OR=2.44, 95% CI 1.28-4.62 p=0.00985. Much
higher risk was connected with the short/short genotype,
OR=6.02, 95% CI 2.10-17.19, p=0.00095. The same trend
was observed in the BRCAx group. OR=2.75, 95% CI 1.44-5.26
p=0.00339 was calculated for the long/short genotype and also
higher risk was found for the short/short genotype, OR=4.60,
95% CI 1.75-12.14, p=0.000300
The length of CA repeats in the ESRβ gene was not statistically
significant except for genotypes long/short and short/short in the
BRCAx group. They were a bit more protective against malignancy
than in the BRCA1/2 group; OR=0.65, 95% CI 0.35-1.22, and
OR=0.60, 95% CI 0.35-1.22, respectively were not statistically
significant but OR=0.64, 95% CI 0.36-1.14 for both genotypes
was statistically significant  (p=0.04375).
These results suggest that dinucleotide repeats in introns of
ESRα and ESRβ genes could be associated with modulation of
breast and ovary risk in hereditary breast and ovarian cancer
families.
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The variable penetrance of breast cancer in BRCA1 mutation
carriers suggests that other genetic or environmental factors
modify breast cancer risk. The C to T transition in the 3´
untranslated region of the prohibitin (PHB) gene alters mRNA
function and has been shown to be associated with an increased
breast cancer risk among young North-American women who
have one first-degree relative with breast cancer.  
To investigate whether the PHB 3´UTR polymorphism acts
as a modifier of hereditary breast cancer risk we performed a
case-control study among female BRCA1 mutation carriers,
which included 258 cases and 258 unaffected controls who had
both breasts and ovaries intact. Controls were matched to cases
by year of birth and BRCA1 mutation (5382insC, 300 T>G,
4153delA).  
Genotyping analysis was performed using RFLP-PCR. Odds
ratios (OR) were calculated using conditional Maximum
Likelihood Estimation for 2x2 tables and Penalized Maximum
Likelihood Estimation for logistic regression.  
Comparison of frequencies among cases and controls
revealed CT (OR, 2.03; 95% CI, 1.17–3.59), TT (OR, 3.17;
95% CI, 0.56–32.25) and combined CT+TT (OR, 2.12; 95%
CI, 1.23–3.70) genotypes as significant modifiers of breast
cancer risk. Breast cancer risk did not differ between carriers of
the 300 T>G and 5382insC mutations. Our results suggest that
the PHB 3´UTR T allele increases the incidence of breast cancer
in patients who are already at increased risk of disease.H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2006; 4(1) 65
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It has been estimated that the lifetime risk of breast cancer
among women who inherit a BRCA1 or BRCA2 mutation is as
high as 80%, and the risk estimates for ovarian cancer range
from 15 to 40%. Several environmental and lifestyle factors are
believed to contribute to the development of breast cancer in
the general population and it is of interest to establish if these
factors operate among mutation carriers as well. To evaluate the
effects of age of menarche, parity, breast-feeding, oophorectomy
and oral contraceptive use, as well as smoking and coffee
consumption, on the risks of breast and ovarian cancer, we
conducted a matched case-control study of Polish women with
BRCA1 mutations. There were 348 breast cancer patients, 150
ovarian cancer patients and similar numbers of age-matched
controls. BRCA1 carriers with late age of menarche, lower parity
and long-term breast-feeding were less likely to develop breast
cancer. Oral contraceptives protected against ovarian cancer.
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Mutations in the BRCA2 gene are one of the two major causes
of hereditary breast cancer. Protein-truncating mutations of BRCA2
are usually deleterious and increase the risk of breast cancer up to
80% over a lifetime. A few missense mutations in BRCA2 are believed
to have a similarly high penetrance, apart from more common
neutral polymorphisms. It is often difficult to classify a particular
sequence variant as a mutation or a polymorphism. For a deleterious
variant, one would expect a greater allele frequency in breast cancer
cases than in ethnic-matched controls. In contrast, neutral
polymorphic variants should be equally frequent in the two groups.
We genotyped 3,241 cases of breast cancer diagnosed at
under 51 years of age, unselected for family history, from 18
hospitals throughout Poland and 2,791 ethnic-matched controls
for a single BRCA2 C5972T variant.
The variant was present in approximately 6% of the Polish
population. In the study, 13 women (11 cases and two controls
(OR=4.7; p=0.02)) were homozygous for the variant allele.
The overall odds ratio for breast cancer in women with a single
copy of the BRCA2 C5972T variant was 1.1 (p=0.7); however,
the effect was significant for patients diagnosed at or before age
40 (OR=1.4; p=0.04). We reviewed the association between
the BRCA2 variant in different histologic subgroups and found
the effect most pronounced in women who had ductal carcinoma
in situ (DCIS) with micro-invasion (OR=2.8; p<0.0001).
The BRCA2 C5972T allele is a common variant in Poland that
increases the risk of DCIS with micro-invasion. The homozygous
state is rare but increases the risk of breast cancer five-fold.
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Pancreatic cancer is an aggressive and devastating disease,
which is characterized by invasiveness, rapid progression and
profound resistance to treatment. 
According to the data from the year 2000, pancreatic cancer
is one of 10 of the most frequent malignancies in the Polish
population. Up to now no gene has been identified as specifically
predisposing to pancreatic cancer. To gain insight into the possible
role of germline BRCA2 mutations in pancreatic cancer, we
studied a group of Polish families with aggregation of this tumour.
We report the BRCA2 germline mutation status of 27 families
with familial pancreatic cancer. The pancreatic carcinoma families
in our study come from the Polish population and did not fulfil
the criteria for hereditary breast and ovarian cancer syndrome or
any other known tumour syndrome. The median age at diagnosis
of pancreatic cancer in these families was 58 years. Using
sequencing analysis, we found BRCA2 germline changes: 203
G>A, 353 A>G, IVS 1029+56 C>T, 3199 A>G, 3624 A>G,
3744 G>A, 4035 T>C, 4296 G>A, 4486 G>T, 5427 C>T.
Three of them are known as unclassified variants, so the
pathogenic roles of these variants are unknown. The rest of the
detected changes are considered to be non-pathogenic, because
they are synonymous mutations and do not cause protein change.
It could be extremely important to check the frequency of
BRCA2 mutations in a larger number of Polish cases of
pancreatic cancer patients. Our study could also indicate that
further work is necessary to characterize other unknown inherited
susceptibility genes in Polish pancreatic cancer patients.
[19]
High Frequency of Selected Founder Mutations in Russian Breast Cancer
Patients
Imyanitov E., Sokolenko A., Iyevleva A., Chekmariova E.,
Buslov K., Suspitsin E., Togo A., Bit-Sava E., Semiglazov V. 
N.N. Petrov Institute of Oncology, St.-Petersburg, Russian Federation
BRCA1 5382insC, CHEK2 1100delC and NBS1 657del5
mutations appear to be relatively common in breast cancer patients
originating from Slavic countries. Here we applied a case-control
study design in order to evaluate the impact of these variants onH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2006; 4(1) 66
BC incidence in St. Petersburg, Russia. High frequency of the
BRCA1 5382insC allele was detected in a group of bilateral breast
cancer patients (10.4%; 15/144). Randomly selected unilateral
BC cases demonstrated noticeable occurrence of the BRCA1
5382insC mutation as well (3.7%; 32/857), with an evident excess
of  carriers in the early-onset (</=40 years) category (6.1%; 6/99)
and in patients reporting breast and/or ovarian tumours in
first-degree relatives (11.3%; 11/97). Strikingly, none of the 478
middle-aged controls and 344 elderly tumour-free women carried
the 5382insC variant. CHEK2 1100delC demonstrated more
modest penetrance, being present in 7/121 (5.8%) bilateral BC,
14/758 (1.8%) unilateral BC, 3/351 (0.9%) healthy donors and
0/344 elderly controls. The corresponding numbers for  NBS1
657del5 were marginal and approached 2/173 (1.2%), 5/700
(0.7%), 2/348 (0.6%) and 0/348 (0%). The presented data
confirm a noticeable contribution of founder mutations in BC
development and Russia: in total BRCA1 5382insC, CHEK2
1100delC and NBS1 657del5 variants may explain up to 6% of
unselected BC cases and up to 20% of familial-like BC diagnoses.
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CYP1A1 and CYP1B1 are two major enzymes of the
cytochrome P450 family and are involved in the hydroxylation of
pro-carcinogens to carcinogens. CYP1B1 exceeds CYP1A1 in its
catalytic efficiency as a hydrolase, which indicates that CYP1B1 is
one of the key players in the carcinogenesis process. The hydroxylation
activity of CYP1B1 is of particular importance, because activated
carcinogens induce single-strand DNA breaks, thereby increasing the
risk of genetic mutation. CYP1B1 metabolises oestradiol to the catechol
oestrogen 4-hydroxyestradiol, which has been shown to induce
depurination of DNA and lead to DNA mutations. In addition to
oestrogens, CYP1B1 bioactivates a range of chemically diverse
pro-carcinogens into carcinogens, including benzo[a]pyrene.
Four polymorphisms of the CYP1B1 gene result in amino acid
replacement – at codons 48, 119, 432  and 453. Polymorphisms
at codons 119 and 432 show high catalytic activity in the region
with recognized functional activity – heme-binding region and
presumed substrate recognition site 1 (SRS1) of  CYP1B1.
We inquired whether the A119S T/T variant of CYP1B1 might
predispose to breast and other cancers in Poland. We genotyped
2,033 cases of breast cancer, unselected for family history, from
13 hospitals throughout Poland and 3,353 cases of the control
population, consisting of a mixture of 2,056 unselected infants
and 1,297 randomly selected individuals. We genotyped cases
from an additional 11 other cancer sites: bladder, colon, kidney,
larynx, lung, melanoma, ovary, pancreatic, prostate, stomach
and thyroid. The registry for each cancer site contains unselected,
histopathologically confirmed cases. 
The A119S T/T genotype was present in 11.4% of breast
cancer cases and 8.4% of controls (OR=1.4, p=0.0005). For
seven of the 11 cancer sites the prevalence of the A119S T/T
allele exceeded 10%. The excess was statistically significant for
three: lung cancer (OR=1.4%; 95% CI: 1.0–1.9), prostate
cancer (OR=1.4; 95% CI: 1.0–1.8) and laryngeal cancer
(OR=1.5; 95% CI: 1.1–2.2).
In this large multi-site study we show that the CYP1B1 A119S
T/T variant appears to be a low penetrance breast cancer
susceptibility gene in Poland and it may predispose to cancers
of other sites as well. There was suggestive evidence for an effect
on the risk of larynx, lung and prostate cancer as well. These
associations should be confirmed in other populations.
[21]
Association between Early-Onset Breast and Laryngeal Cancers
Jaworowska E.
1, Masojæ B.
2, Tarnowska C.
1, Brzosko M.
3,
Fliciñski J.
3, Serrano-Fernandez P .
2, Matyjasik J.
2, Amernik K.
1,
Scott R.J.
4, Lubiñski J.
2
1Department of Otolaryngology and Laryngological Oncology, Pomeranian Medical
University, Szczecin, Poland; 2International Hereditary Cancer Center, Department of
Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland; 3Department
of Reumatology, Pomeranian Medical University, Szczecin, Poland; 4Discipline of Medical
Genetics, Faculty of Health, University of Newcastle, and the Hunter Medical Research
Institute, Newcastle, NSW Australia
Recent studies suggest that there is a group of genes that pre-
dispose simultaneously to both early-onset breast and laryngeal
cancer. Studies were performed on a large series of unselected pa-
tients with laryngeal cancer diagnosed in Szczecin, Poland. Pedi-
grees of 683 laryngeal cancer patients were analysed for frequen-
cy of early-onset and late-onset breast cancer among first-degree
relatives. The observed frequencies of breast cancer in these fami-
lies were compared to those expected. In addition, common mu-
tations/variants in the three genes BRCA1, NOD2 and CYP1B1,
known to be associated with early-onset breast cancer, were as-
sessed to determine their frequency in 348 unselected laryngeal
cancers. The average age at diagnosis of LC among patients who
had relatives affected by BC diagnosed under the age of 50 years
was 57.62. In comparison, LC patients reporting a first-degree re-
lative affected by BC diagnosed above 50 years of age had an
average age of diagnosis of 66.00 years, which was significantly
different (p=0.0064). Similarly, the average age of diagnosis of
BC among patients with LC diagnosed under the age of 50 years
was 46.7 years,  whereas LC patients with tumours diagnosed abo-
ve 50 years had relatives diagnosed with breast cancer at an ave-
rage age of 53.37 years, which was significantly different (p=0.02). 
From the 348 consecutive ascertained laryngeal cancer
patients who had molecular studies undertaken, breast cancers
among first-degree relatives were found in 18 families including
8 with breast cancers diagnosed at less than 50 years of age.
A molecular basis was identified (the CYP1B1 355T/T genotype)
in only 2 of the 8 early cases, suggestive of there being
additional, as yet unknown genes that are associated with an
early-onset laryngeal-breast cancer phenotype. 
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Both breast and lung cancers are common malignancies, and
within the context of known genetic predispositions to breast cancer,
no association has been made in linking the two diseases together.
This does not exclude the possibility that such associations may exist
that lie outside the known high-risk breast cancer families. To
examine the likelihood of common genetic factors that could
influence the risk of disease, two sets of consecutively collected
tumour groups were examined for the 3020insC mutation in the
NOD2/CARD15 gene. A total of 4,107 consecutively collected
breast cancer patients were assessed for prevalence of the 3020insC
mutation and compared to a consecutively collected series of 389
lung cancer patients and 2068 control samples. The results revealed
that a proportion of breast cancer patients who had a first- or a
second-degree relative diagnosed with lung cancer were more likely
to harbour a change in NOD2/CARD15 compared to patients
who had no relatives affected by lung cancer. Furthermore, this
difference appeared to be specific to the breast and lung cancer
subgroup since there was no difference in the frequency of the
3020insC allele in the consecutively collected lung cancer patients. 
In conclusion, it appears that the 3020insC mutation of the
NOD2/CARD15 gene may be a genetic predisposing factor for
aggregations of breast and lung cancer.  
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Mutations of the CHEK2 Gene in Patients with Borderline Cystadenomas
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Borderline tumours are noninvasive neoplasms that have
nuclear abnormalities and mitotic activity intermediate between
benign and malignant tumours. The most common borderline
surface epithelial-stromal lesions of the ovary are serous and
mucinous tumors, which may undergo malignant transformation
into cystadenocarcinoma.   
Recently it was found that CHEK2 is a multiorgan cancer
susceptibility gene. Mutations in the CHEK2 gene have been
associated with a predisposition to breast, colon, kidney, prostate
and thyroid cancer. We examined borderline cystadenomas for
occurrence of three founder alleles characteristic for the Polish
population.
The study group comprised 119 female patients with
borderline ovarian cystdenoma: 87 with serous type and 32 with
mucinous type. Cystadenoma cases were collected from five
provinces of Poland between 1997 and 2005. Study subjects
were unselected for age and for family history. The control group
consisted of 4,000 individuals.
The missense variant of CHEK2 gene was present in 11.8%
of women with borderline cystadenomas and 4.8% in controls
(OR=2.6; p=0.0014). This positive association was also found
for serous cystadenoma of borderline malignancy (OR=3.2;
p=0.0004). Relative risk was increased particularly for
cystadenomas diagnosed under the age of 50 years (OR=2.7;
p=0.006 for all cases and OR=3.04; p=0.0066 for serous
subgroup). Heterozygotes among the mucinous subgroup were
identified as the most frequent in young patients diagnosed under
40 years, but this excess was not statistically significant (OR=2.8;
p=0.3994). We did not find any statistically significant differences
for CHEK2-truncating mutations.
The findings of our study suggest that the I157T variant of
the CHEK2 gene may predispose to borderline cystadenoma in
women at reproductive age. 
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The Molecular Pathway as a Global Genetic Source of Cancer Risk  
Serrano-Fernández P ., Woko³orczyk D., Matyjasik J.,
Dêbniak T., Lubiñski J.
International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian
Medical University, Szczecin, Poland
In recent years several gene mutations have been
demonstrated to be associated with an increased risk of
developing a particular cancer type. Those findings have mostly
been analysed independently. Some genetic risk sources could
in fact affect presumably independent genetic networks (e.g. the
ones responsible for DNA repair versus the ones responsible for
angiogenesis). However, it is reasonable to think that the number
of completely independent networks will be limited and many of
the mutations contributing to increased cancer risk will be
functionally linked in the same pathway.
Known mutations on 7 genes – previously described as
associated with breast cancer in the Polish population – were
checked for their functional interrelationships and a molecular
network was built accordingly. We then analysed the incidence
of mutations on that pathway as a whole in breast cancer patients
(575 individuals) as compared with controls (1,175 individuals).
Moreover we checked for specific dyadic interactions leading to
an unexpectedly high increase of cancer risk.
Results significantly show how the cancer risk geometrically
grows with the accumulation of mutations in the predefined
pathway. Logistic regression showed additionally a significant
interaction effect between 2 of the 7 genes.
Considering the whole pathway as a genetic risk source
improves the accuracy of epidemiological models since it takes
into account interactive models, where the final increase in the
cumulative risk does not result just from the addition of the partialH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2006; 4(1) 68
risks associated with each mutation separately. Indirectly, it also
offers – for basic research – a quantitative background for
unravelling regulatory relationships in a pathway.  
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Mutations in the NBS1 gene are associated with Nijmegen
breakage syndrome (NBS) – autosomal recessive disorder. Nibrin,
the product of the NBS1 gene, is functionally involved in the double
strand DNA repair system. Heterozygous carriers of NBS1 mutations
have a strongly increased risk of cancer. The aim of the study was
to analyse the mutations and polymorphisms in the NBS1 gene in
children with different tumours. The blood DNA samples (DBS) of
201 patients and the different tumour DNA samples of 68 patients
were screened for two of the most common mutations in exon 6
of the NBS1 gene: c.657del5 and c.643C>T (p.R215W). The
molecular study of medulloblastoma DNA samples of 38 patients
consisted of analyses of exons 3, 5, 6, 7, 8, 10 and 13. All samples
were analysed by PCR-SSCP and by direct sequencing. The four
NBS1 heterozygous mutations were detected in all analysed
patients. Among the 233 patients the c.657del5 mutation was
identified on one allele in two patients and the c.643C>T
(p.R215W) mutation on one allele in one patient. The frequency
of the c.657del5 mutation was calculated as 0.0043 and the
c.643C>T mutation was 0.0021. The values are similar to the
frequency calculated for the mutations in controls (0.0060 and
0.0030, respectively). In the group of 38 patients with
medulloblastoma, one heterozygous carrier for the c.511A>G
(p.I171V) mutation in exon 5 of the NBS1 gene was identified. In
addition, three frequent sequence variants, c.553A>G (p.E185Q),
c.2016A>G (p.P672P), and IVS12-7A>G, were revealed. Larger
studies are needed to evaluate the impact of  NBS1 gene hetero-
zygosity in susceptibility to paediatric brain tumours.   
This study was supported by grant No. PBZ/KBN-17 from
the Polish Ministry of Education and Science.
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Cancer Familial Aggregation (CFA) and G446A Polymorphism 
in the ARLTS1 Gene
Masojæ B., Mierzejewski M., Cybulski C., Van de Wetering T.,
Dêbniak T., Górski B., Jaworowska E., Lener M., Scott R.J.,
Lubiñski J.
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ARLTS1 – a member of the ADP-ribosylation factor family –
is a newly-described candidate tumour suppressor gene. Recent
studies show that a nonsense polymorphism, G446A
(Trp149Stop), in the ARLTS1 gene is significantly more frequent
in familial cancer cases than in sporadic cancer cases. This study
presents an analysis of the germline G446A polymorphism in
the ARLTS1 gene among 1,686 consecutively collected patients
with breast cancer, prostate cancer, malignant melanoma, thyroid
papillary cancer or laryngeal cancer  in Poland. The G446A
allele was present in 1.81% (9/497) of breast cancer patients,
1.46% (5/343) of prostate cancer patients, 1.76% (7/397) of
melanoma patients, 1.65% (3/182) of thyroid papillary
carcinoma patients and 2.68% (8/299) of laryngeal cancer
patients. The frequency of this polymorphism in the control group
was 1.45% (8/552). Differences in the frequency of the G446A
polymorphism between case and control groups were not
statistically significant. In addition, there was no significant
difference in the number of Cancer Familial Aggregations (CFA)
among breast, prostate, thyroid or laryngeal cancer cases
harbouring the G446A polymorphism, when compared to the
G446A negative cases. Interestingly, out of the CFA melanoma
cases, 4/6 (66.6%) were found to harbour the change compared
to only 20.2% (69/341) of sporadic melanoma cases. This
difference was statistically significant (p=0.02, OR=7.8). The
results of this study suggest that the G446A in ARLTS1 gene is
probably not associated with an increased risk of sporadic breast
cancer, prostate cancer, melanoma, thyroid papillary cancer or
laryngeal cancer. Moreover, the G446A polymorphism is not
significantly more frequent in CFA cases except for families in
which the proband had melanoma. To confirm this result more
cases of melanoma should be analysed.
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Primary Cutaneous T-Cell Lymphomas Show a Deletion 
or Translocation Affecting NAV3, the Human UNC-53 Homologue 
– the Lesson from Chromosome Aberrations for Suppressor Gene Finding 
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Multicolour fluorescent in situ hybridization (FISH) was used
to identify acquired chromosomal aberrations in 12 patients with
mycosis fungoides or Sezary syndrome, the most common forms
of primary cutaneous T-cell lymphoma (CTCL). The most
frequently affected chromosome was 12, which showed clonal
deletions or translocations with a break point in 12q21 or 12q22
in five of seven consecutive Sezary syndrome patients and a clonal
monosomy in the sixth patient. The break point of a balanced
translocation t(12;18)(q21;q21.2), mapped in the minimal
common region of two deletions, fine mapped to 12q2. By
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locus-specific FISH, the translocation disrupted one gene, NAV3
(POMFIL1), a human homologue of unc-53 in Caenorhabditis
elegans. A missense mutation in the remaining NAV3 allele was
found in one of six cases with a deletion or translocation. With
locus-specific FISH, NAV3 deletions were found in the skin lesions
of four of eight (50%) patients with early mycosis fungoides (stages
IA-IIA) and in the skin or lymph node of 11 of 13 (85%) patients
with advanced mycosis fungoides or Sezary syndrome. Preliminary
functional studies with lentiviral small interfering RNA-based NAV3
silencing in Jurkat cells and in primary lymphocytes showed
enhanced interleukin 2 expression (but not CD25 expression).
Thus, NAV3 may contribute to the growth, differentiation, and
apoptosis of CTCL cells as well as to the skewing from Th1-type
to Th2-type phenotype during disease progression. NAV3, a novel
putative haploinsufficient tumour suppressor gene, is disrupted
in most cases of the commonest types of CTCL and may thus
provide a new diagnostic tool.
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The Challenge of Individualizing Genetic Counselling 
in Cancer Families – a Case Report
Pesz K., Trusewicz A., Œlêzak R., S¹siadek M. 
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Although the pedigree criteria for hereditary breast and
ovarian cancer and indications for DNA testing seem to be clearly
established from time to time, a snag arises when the pedigree
does not reveal a conclusive pattern for cancer inheritance,
making the cancer risk assessment difficult. Then the benefit/risk
ratio of offering or not offering molecular testing must be taken
into account by the genetic counselling provider. To illustrate this
point we present a family with a pedigree that seemed disputable
as far as BRCA1 testing was concerned. The proband was seeking
genetic counselling after losing three of his closest relatives to
cancer. Taking the pedigree into consideration the diagnostic
algorithm for testing was established. Overall we searched for
10 different mutations in five different genes. Finding BRCA1
mutation carriers in this family enabled us to make the diagnosis
of hereditary breast/ovarian cancer syndrome. It can be concluded
from the study that each family should be treated individually and
genetic counselling provides an opportunity for it.
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Cost Effectiveness Analysis of a Prophylactic, Genetic-Oncological
Programme in the West Pomeranian Region – Initial Announcement 
of Results
Marska N. 
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One area of disability policy is prevention, which is described
as reducing the risk of entering an undesirable state. Most areas
of intervention analysed so far have considered protection and
promotion, and they are well developed and expensive. Because
it is difficult to take the awarded rights back and disability assessment
is a complicated issue, the best way is to limit the application
number. This is why the problem of prevention, and within it also
prophylaxis, has become the centre of attention. Furthermore, the
problem of social expenses rises especially within prevention
programmes, where simple economic models are difficult to
implement. After 1989, the supremacy of financial aspects over
social ones caused a shortage in epidemiological research.
An example of prophylactic activity in cancer prevention is
the Centre of Hereditary Tumours located at Pomeranian Medical
University in Szczecin. Since 2003 the author of this paper in
cooperation with Prof. Jan Lubiñski, the Head of the Centre and
the national consultant of clinical genetics, has conducted a
research programme titled: Cost effectiveness analysis of a
prophylactic, genetic-oncological programme in the West
Pomeranian region. The main aim is to identify, evaluate and
compare the real costs of a prophylactic programme with the
direct and most indirect costs, coming from breast and ovarian
cancer. To achieve this it was necessary to identify and calculate
the costs of the questionnaire programme conducted during
1999-2003, the costs of the prophylactic programme – ‘to lead
off’ the patient during the following years, the real costs of medical
treatment, the real costs coming from social insurance benefits
paid to patients and the potential costs of temporary or permanent
exclusion from the working population. Such kinds of research
are being carried out in Poland for the first time. There were some
tests taken, though only for direct costing. The research group
consisted mainly of patients with breast cancer and a few with
breast and ovarian cancer, for which diagnosis has been made
in 1999-2000. The social costs were evaluated for the period
2000-2003 (treatment, recovery and rehabilitation).
The medical costs of cancer treatment (breast or breast and
ovarian) were around USD 6,500 and were calculated for the
full treatment procedure (usually 3 years). The indirect cost – the
amount of disability pension and additional benefits received
during 4 analysed years – was USD 10,330. The economic cost
– the lost GDP – if calculated for the total population equals
USD 26,650, and if calculated for the population active on the
labour market equals USD 59,112. Conclusively, the total cost
amounts to a minimum of USD 43,500, that is USD 10,870 per
year on average. Taking into consideration the costs of screening
tests, the costs of periodical examinations of patients with BRCA1
or BRCA2, the preventive surgery and the reduction of probability
of an illness, the total cost per person equals USD 6,000, but
this is spread out over many years. 